PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för selumetinib. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

21 hits

Bibliografisk träff 2015-10-07

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.

Holkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, Baz R, Korde N, Lin HY, Chen JQ, Herrmann M, Xi L, Raffeld M, Zhao X, Wan W, Tombes MB, Shrader E, Weir-Wiggins C, Sankala H, Hogan KT, Doyle A, Annunziata CM, Wellons M, Roberts JD, Sullivan D, Landgren O, Grant S.

Clin Cancer Res · clinical trial, phase ii; research support, n.i.h., intramural; research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-15-1076

Bibliografisk träff 2015-09-17

MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model.

Bartholomeusz C, Xie X, Pitner MK, Kondo K, Dadbin A, Lee J, Saso H, Smith PD, Dalby KN, Ueno NT.

Mol Cancer Ther · research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1535-7163.mct-15-0243

Bibliografisk träff 2015-06-10

Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).

Carvajal RD, Schwartz GK, Mann H, Smith I, Nathan PD.

BMC Cancer · clinical trial, phase iii; research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1186/s12885-015-1470-z

Bibliografisk träff 2015-04-14

A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study.

Coleman RL, Sill MW, Thaker PH, Bender DP, Street D, McGuire WP, Johnston CM, Rotmensch J.

Gynecol Oncol · clinical trial, phase ii; research-article; multicenter study; journal article; research support, n.i.h., extramural · DOI 10.1016/j.ygyno.2015.04.005

Bibliografisk träff 2015-02-01

Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer.

Do K, Speranza G, Bishop R, Khin S, Rubinstein L, Kinders RJ, Datiles M, Eugeni M, Lam MH, Doyle LA, Doroshow JH, Kummar S.

Invest New Drugs · clinical trial, phase ii; research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1007/s10637-015-0212-z

Bibliografisk träff 2014-12-11

The glucosylceramide synthase inhibitor PDMP sensitizes pancreatic cancer cells to MEK/ERK inhibitor AZD-6244.

Wang T, Wei J, Wang N, Ma JL, Hui PP.

Biochem Biophys Res Commun · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbrc.2014.12.019

Bibliografisk träff 2014-11-11

Selumetinib for the treatment of cancer.

Ciombor KK, Bekaii-Saab T.

Expert Opin Investig Drugs · journal article · DOI 10.1517/13543784.2015.982275

Bibliografisk träff 2014-10-25

BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.

Ku BM, Jho EH, Bae YH, Sun JM, Ahn JS, Park K, Ahn MJ.

Invest New Drugs · research support, non-u.s. gov't; journal article · DOI 10.1007/s10637-014-0163-9

Bibliografisk träff 2014-10-23

Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation.

Grasso S, Tristante E, Saceda M, Carbonell P, Mayor-López L, Carballo-Santana M, Carrasco-García E, Rocamora-Reverte L, García-Morales P, Carballo F, Ferragut JA, Martínez-Lacaci I.

Neoplasia · research support, non-u.s. gov't; research-article; journal article · DOI 10.1016/j.neo.2014.08.011

Bibliografisk träff 2014-10-17

Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.

Hochster HS, Uboha N, Messersmith W, Gold PJ, ONeil BH, Cohen D, Denlinger C, Cohen S, Leichman CG, Leichman L, Lenz HJ.

Cancer Chemother Pharmacol · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1007/s00280-014-2609-3

Bibliografisk träff 2013-08-13

Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.

Beloueche-Babari M, Jamin Y, Arunan V, Walker-Samuel S, Revill M, Smith PD, Halliday J, Waterton JC, Barjat H, Workman P, Leach MO, Robinson SP.

Br J Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/bjc.2013.456

Bibliografisk träff 2013-02-26

Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.

Catalanotti F, Solit DB, Pulitzer MP, Berger MF, Scott SN, Iyriboz T, Lacouture ME, Panageas KS, Wolchok JD, Carvajal RD, Schwartz GK, Rosen N, Chapman PB.

Clin Cancer Res · clinical trial, phase ii; research support, american recovery and reinvestment act; research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-12-3476

Bibliografisk träff 2012-09-12

Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.

Patel SP, Lazar AJ, Papadopoulos NE, Liu P, Infante JR, Glass MR, Vaughn CS, LoRusso PM, Cohen RB, Davies MA, Kim KB.

Cancer · multicenter study; clinical trial, phase i; journal article · DOI 10.1002/cncr.27790

Bibliografisk träff 2012-05-08

Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines.

Ma BB, Lui VW, Cheung CS, Lau CP, Ho K, Hui EP, Tsui SK, Ng MH, Cheng SH, Ng PK, Tsao SW, Chan AT.

Invest New Drugs · research support, non-u.s. gov't; journal article · DOI 10.1007/s10637-012-9828-4

Bibliografisk träff 2012-05-01

(18)F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors.

Desar IM, Gilles R, van Herpen CM, Timmer-Bonte AJ, Cantarini MV, van der Graaf WT, Oyen WJ.

World J Nucl Med · research-article; journal article · DOI 10.4103/1450-1147.103413

Bibliografisk träff 2012-03-07

Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma.

Patel SP, Kim KB.

Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543784.2012.665871

Bibliografisk träff 2012-02-16

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.

Holt SV, Logié A, Odedra R, Heier A, Heaton SP, Alferez D, Davies BR, Wilkinson RW, Smith PD.

Br J Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/bjc.2012.8

Bibliografisk träff 2012-01-12

Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements.

Hayes DN, Lucas AS, Tanvetyanon T, Krzyzanowska MK, Chung CH, Murphy BA, Gilbert J, Mehra R, Moore DT, Sheikh A, Hoskins J, Hayward MC, Zhao N, O'Connor W, Weck KE, Cohen RB, Cohen EE.

Clin Cancer Res · clinical trial, phase ii; research-article; multicenter study; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-11-0563

Bibliografisk träff 2011-05-19

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.

Bodoky G, Timcheva C, Spigel DR, La Stella PJ, Ciuleanu TE, Pover G, Tebbutt NC.

Invest New Drugs · clinical trial, phase ii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1007/s10637-011-9687-4

Bibliografisk träff 2010-10-27

Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886).

Balagula Y, Barth Huston K, Busam KJ, Lacouture ME, Chapman PB, Myskowski PL.

Invest New Drugs · research support, non-u.s. gov't; research-article; journal article; case reports · DOI 10.1007/s10637-010-9567-3

Bibliografisk träff 2010-04-21

Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice.

Denton CL, Gustafson DL.

Cancer Chemother Pharmacol · research-article; journal article; research support, n.i.h., extramural · DOI 10.1007/s00280-010-1323-z